Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for anti-inflammatory effect in patients undergoing coronary artery bypass graft surgery
IRCT20220907055908N1Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Oct 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by Semnan University of Medical Sciences. Primary endpoints: C-reactive protein serum level and Interleukin 6. Started Oct 2022; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20220907055908N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220907055908N1.